Cardinal Health (NYSE:CAH) Updates FY 2025 Earnings Guidance

Cardinal Health (NYSE:CAH) updated its FY 2025 earnings guidance on Friday. The company provided EPS guidance of 7.900-7.900 for the period, compared to the consensus EPS estimate of 8.720. The company issued revenue guidance of -.

Cardinal Health Trading Down 0.6 %

CAH stock opened at $126.27 on Friday. The firm has a 50 day simple moving average of $120.75 and a 200-day simple moving average of $111.81. The company has a market capitalization of $30.56 billion, a P/E ratio of 24.57, a PEG ratio of 1.48 and a beta of 0.63. Cardinal Health has a twelve month low of $93.17 and a twelve month high of $127.27.

Cardinal Health (NYSE:CAH) last issued its quarterly earnings results on Friday, November 1st. The company reported $1.88 EPS for the quarter, topping the consensus estimate of $1.62 by $0.26. Cardinal Health had a net margin of 0.56% and a negative return on equity of 56.56%. The business had revenue of $52.28 billion for the quarter, compared to analysts’ expectations of $50.90 billion. During the same quarter last year, the company posted $1.73 earnings per share. The company’s quarterly revenue was down 4.3% compared to the same quarter last year. On average, research analysts predict that Cardinal Health will post 7.82 EPS for the current year.

Cardinal Health Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd were paid a dividend of $0.5056 per share. This represents a $2.02 annualized dividend and a yield of 1.60%. The ex-dividend date of this dividend was Thursday, January 2nd. Cardinal Health’s dividend payout ratio (DPR) is presently 39.30%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on CAH. Morgan Stanley increased their target price on shares of Cardinal Health from $127.00 to $136.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Barclays increased their price objective on shares of Cardinal Health from $117.00 to $133.00 and gave the stock an “overweight” rating in a research note on Monday, November 4th. Wells Fargo & Company raised Cardinal Health from an “underweight” rating to an “equal weight” rating and upped their target price for the company from $101.00 to $127.00 in a report on Friday, December 13th. UBS Group raised their price target on Cardinal Health from $134.00 to $139.00 and gave the stock a “buy” rating in a report on Monday, November 4th. Finally, Citigroup upped their price objective on Cardinal Health from $120.00 to $129.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.29.

Cardinal Health Company Profile

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.